| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.27 | 2e-16 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-14 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.31 | 7e-10 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.17 | 7e-08 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-06 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.12 | 3e-05 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.18 | 5e-05 |